DBV Technologies (DBVT) Competitors

DBV Technologies logo
$10.27 -0.75 (-6.81%)
Closing price 04:00 PM Eastern
Extended Trading
$10.26 -0.01 (-0.10%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DBVT vs. ADMA, BEAM, CLDX, PVLA, and SEPN

Should you buy DBV Technologies stock or one of its competitors? DBV Technologies's main competitors and comparable companies include ADMA Biologics (ADMA), Beam Therapeutics (BEAM), Celldex Therapeutics (CLDX), Palvella Therapeutics (PVLA), and Septerna (SEPN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does DBV Technologies compare to ADMA Biologics?

DBV Technologies (NASDAQ:DBVT) and ADMA Biologics (NASDAQ:ADMA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, DBV Technologies had 2 more articles in the media than ADMA Biologics. MarketBeat recorded 4 mentions for DBV Technologies and 2 mentions for ADMA Biologics. DBV Technologies' average media sentiment score of 1.11 beat ADMA Biologics' score of 0.80 indicating that DBV Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DBV Technologies
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ADMA Biologics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ADMA Biologics has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DBV Technologies$5.64M122.86-$146.95M-$3.01N/A
ADMA Biologics$510.17M5.95$146.93M$0.7717.77

DBV Technologies has a beta of -0.84, indicating that its stock price is 184% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

ADMA Biologics has a net margin of 35.14% compared to DBV Technologies' net margin of -5,392.17%. ADMA Biologics' return on equity of 42.56% beat DBV Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
DBV Technologies-5,392.17% -120.95% -88.35%
ADMA Biologics 35.14%42.56%26.96%

DBV Technologies presently has a consensus price target of $45.25, suggesting a potential upside of 310.62%. ADMA Biologics has a consensus price target of $17.50, suggesting a potential upside of 27.92%. Given DBV Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe DBV Technologies is more favorable than ADMA Biologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DBV Technologies
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
ADMA Biologics
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 1.1% of DBV Technologies shares are held by insiders. Comparatively, 3.9% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

ADMA Biologics beats DBV Technologies on 10 of the 16 factors compared between the two stocks.

How does DBV Technologies compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and DBV Technologies (NASDAQ:DBVT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 1.1% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Beam Therapeutics currently has a consensus price target of $47.64, suggesting a potential upside of 108.35%. DBV Technologies has a consensus price target of $45.25, suggesting a potential upside of 310.62%. Given DBV Technologies' higher possible upside, analysts clearly believe DBV Technologies is more favorable than Beam Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beam Therapeutics
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.77
DBV Technologies
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

Beam Therapeutics has higher revenue and earnings than DBV Technologies. Beam Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$146.64M16.14-$79.99M-$1.04N/A
DBV Technologies$5.64M122.86-$146.95M-$3.01N/A

Beam Therapeutics has a net margin of -73.04% compared to DBV Technologies' net margin of -5,392.17%. Beam Therapeutics' return on equity of -32.76% beat DBV Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Beam Therapeutics-73.04% -32.76% -25.80%
DBV Technologies -5,392.17%-120.95%-88.35%

Beam Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.84, meaning that its share price is 184% less volatile than the broader market.

In the previous week, Beam Therapeutics had 20 more articles in the media than DBV Technologies. MarketBeat recorded 24 mentions for Beam Therapeutics and 4 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.11 beat Beam Therapeutics' score of 0.73 indicating that DBV Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Beam Therapeutics
4 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
DBV Technologies
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Beam Therapeutics beats DBV Technologies on 13 of the 17 factors compared between the two stocks.

How does DBV Technologies compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and DBV Technologies (NASDAQ:DBVT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Celldex Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.84, indicating that its stock price is 184% less volatile than the broader market.

71.7% of DBV Technologies shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by insiders. Comparatively, 1.1% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Celldex Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -5,392.17%. Celldex Therapeutics' return on equity of -52.66% beat DBV Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Celldex TherapeuticsN/A -52.66% -47.58%
DBV Technologies -5,392.17%-120.95%-88.35%

DBV Technologies has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celldex Therapeutics$158K14,335.08-$258.76M-$4.30N/A
DBV Technologies$5.64M122.86-$146.95M-$3.01N/A

In the previous week, Celldex Therapeutics had 11 more articles in the media than DBV Technologies. MarketBeat recorded 15 mentions for Celldex Therapeutics and 4 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.11 beat Celldex Therapeutics' score of 0.92 indicating that DBV Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Celldex Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
DBV Technologies
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Celldex Therapeutics currently has a consensus price target of $64.08, indicating a potential upside of 122.28%. DBV Technologies has a consensus price target of $45.25, indicating a potential upside of 310.62%. Given DBV Technologies' higher possible upside, analysts clearly believe DBV Technologies is more favorable than Celldex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77
DBV Technologies
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

Celldex Therapeutics beats DBV Technologies on 9 of the 16 factors compared between the two stocks.

How does DBV Technologies compare to Palvella Therapeutics?

DBV Technologies (NASDAQ:DBVT) and Palvella Therapeutics (NASDAQ:PVLA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

DBV Technologies currently has a consensus target price of $45.25, indicating a potential upside of 310.62%. Palvella Therapeutics has a consensus target price of $213.85, indicating a potential upside of 40.25%. Given DBV Technologies' higher probable upside, analysts plainly believe DBV Technologies is more favorable than Palvella Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DBV Technologies
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Palvella Therapeutics
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
3.00

DBV Technologies has a beta of -0.84, meaning that its share price is 184% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.21, meaning that its share price is 121% less volatile than the broader market.

Palvella Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -5,392.17%. Palvella Therapeutics' return on equity of -44.44% beat DBV Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
DBV Technologies-5,392.17% -120.95% -88.35%
Palvella Therapeutics N/A -44.44%-36.75%

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 1.1% of DBV Technologies shares are held by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Palvella Therapeutics had 20 more articles in the media than DBV Technologies. MarketBeat recorded 24 mentions for Palvella Therapeutics and 4 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.11 beat Palvella Therapeutics' score of 0.97 indicating that DBV Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DBV Technologies
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Palvella Therapeutics
5 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Palvella Therapeutics has higher revenue and earnings than DBV Technologies. Palvella Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DBV Technologies$5.64M122.86-$146.95M-$3.01N/A
Palvella Therapeutics$42.81M52.07-$41.72M-$5.50N/A

Summary

Palvella Therapeutics beats DBV Technologies on 11 of the 17 factors compared between the two stocks.

How does DBV Technologies compare to Septerna?

Septerna (NASDAQ:SEPN) and DBV Technologies (NASDAQ:DBVT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Septerna presently has a consensus price target of $56.44, indicating a potential upside of 32.50%. DBV Technologies has a consensus price target of $45.25, indicating a potential upside of 310.62%. Given DBV Technologies' higher possible upside, analysts clearly believe DBV Technologies is more favorable than Septerna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Septerna
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
DBV Technologies
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Septerna had 23 more articles in the media than DBV Technologies. MarketBeat recorded 27 mentions for Septerna and 4 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.11 beat Septerna's score of 0.11 indicating that DBV Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Septerna
4 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
DBV Technologies
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Septerna has higher revenue and earnings than DBV Technologies. Septerna is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Septerna$96.27M21.04-$48.88M-$1.29N/A
DBV Technologies$5.64M122.86-$146.95M-$3.01N/A

Septerna has a beta of 2.2, meaning that its share price is 120% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.84, meaning that its share price is 184% less volatile than the broader market.

Septerna has a net margin of -61.29% compared to DBV Technologies' net margin of -5,392.17%. Septerna's return on equity of -14.98% beat DBV Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Septerna-61.29% -14.98% -10.03%
DBV Technologies -5,392.17%-120.95%-88.35%

71.7% of DBV Technologies shares are held by institutional investors. 5.8% of Septerna shares are held by insiders. Comparatively, 1.1% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Septerna beats DBV Technologies on 12 of the 17 factors compared between the two stocks.

Get DBV Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DBVT vs. The Competition

MetricDBV TechnologiesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$645.78M$4.07B$7.83B$11.75B
Dividend YieldN/A3.64%2.47%4.41%
P/E Ratio-3.4124.2434.3430.11
Price / Sales114.5014.858.005.34
Price / CashN/A21.8921.0222.34
Price / Book2.454.354.763.85
Net Income-$146.95M-$24.19M$3.52B$393.14M
7 Day Performance-7.06%-7.26%-5.34%-4.53%
1 Month Performance13.48%-4.96%-3.61%-5.86%
1 Year Performance-22.43%-2.87%0.01%-7.78%

DBV Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DBVT
DBV Technologies
3.8667 of 5 stars
$10.27
-6.8%
$45.25
+340.6%
-16.8%$645.78M$5.64MN/A125
ADMA
ADMA Biologics
3.9298 of 5 stars
$12.64
-1.2%
$17.50
+38.5%
-12.1%$2.83B$510.17M16.40647
BEAM
Beam Therapeutics
2.7368 of 5 stars
$25.12
-7.0%
$47.36
+88.5%
+5.3%$2.60B$139.74MN/A540
CLDX
Celldex Therapeutics
2.0827 of 5 stars
$30.76
-1.5%
$64.08
+108.3%
+12.8%$2.41B$1.54MN/A198
PVLA
Palvella Therapeutics
2.6388 of 5 stars
$166.65
-4.3%
$213.85
+28.3%
+82.1%$2.40B$42.81MN/A29

Related Companies and Tools


This page (NASDAQ:DBVT) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners